For research use only. Not for therapeutic Use.
Nimucitinib is a Janus kinase (JAK) inhibitor[1].
| Catalog Number | I041971 |
| CAS Number | 2740557-24-6 |
| Synonyms | 4-[(3,5-difluorophenyl)methylamino]-6-[3-[[(3S)-piperidine-3-carbonyl]amino]anilino]pyridine-3-carboxamide |
| Molecular Formula | C25H26F2N6O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H26F2N6O2/c26-17-7-15(8-18(27)9-17)12-30-22-11-23(31-14-21(22)24(28)34)32-19-4-1-5-20(10-19)33-25(35)16-3-2-6-29-13-16/h1,4-5,7-11,14,16,29H,2-3,6,12-13H2,(H2,28,34)(H,33,35)(H2,30,31,32)/t16-/m0/s1 |
| InChIKey | FDQSOYXLRVBMGA-INIZCTEOSA-N |
| SMILES | C1CC(CNC1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=C3)NCC4=CC(=CC(=C4)F)F)C(=O)N |
| Reference | [1]. WHO Drug Information, Vol. 36, No. 4, 2022. |
